TY - JOUR T1 - Direct RNA nanopore sequencing of SARS-CoV-2 extracted from critical material from swabs JF - medRxiv DO - 10.1101/2020.12.21.20191346 SP - 2020.12.21.20191346 AU - Davide Vacca AU - Antonino Fiannaca AU - Fabio Tramuto AU - Valeria Cancila AU - Laura La Paglia AU - Walter Mazzucco AU - Alessandro Gulino AU - Massimo La Rosa AU - Carmelo Massimo Maida AU - Gaia Morello AU - Beatrice Belmonte AU - Alessandra Casuccio AU - Rosario Maugeri AU - Gerardo Iacopino AU - Francesco Vitale AU - Claudio Tripodo AU - Alfonso Urso Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/23/2020.12.21.20191346.abstract N2 - Background In consideration of the increasing prevalence of COVID-19 cases in several countries and the resulting demand for unbiased sequencing approaches, we performed a direct RNA sequencing experiment using critical oropharyngeal swab samples collected from Italian patients infected with SARS-CoV-2 from the Palermo region in Sicily.Methods Here, we identified the sequences SARS-CoV-2 directly in RNA extracted from critical samples using the Oxford Nanopore MinION technology without prior cDNA retro-transcription.Results Using an appropriate bioinformatics pipeline, we could identify mutations in the nucleocapisid (N) gene, which have been reported previously in studies conducted in other countries.Conclusion To the best of our knowledge, the technique used in this study has not been used for SARS-CoV-2 detection previously owing to the difficulties in the extraction of RNA of sufficient quantity and quality from routine oropharyngeal swabs.Despite these limitations, this approach provides the advantages of true native RNA sequencing, and does not include amplification steps that could introduce systematic errors.This study can provide novel information relevant to the current strategies adopted in SARS-CoV-2 next-generation sequencing.We deposited the gene sequence in the NCBI database under the following URL:https://www.ncbi.nlm.nih.gov/nuccore/MT457389Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by AIRC (Associazione Italiana per la Ricerca sul Cancro)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:EC N˚11/18DEC2020 - University of Palermo - Department of Sciences for Health Promotion and Mother-Child Care G. D Alessandro - Piazza delle cliniche N˚2 - zip code 90127 -Palermo - Italy.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe undersigned Davide Vacca and Antonino Fiannaca as first coauthors of the titled manuscript "Direct RNA nanopore sequencing of SARS-CoV-2 extracted from critical material from swabs", declare that all data referred to this work are aviable for scientific aimes. https://www.ncbi.nlm.nih.gov/nuccore/MT457389 ER -